PCSA

PROCESSA PHARMACEUTICALS, INC.

PCSA · CIK 1533743 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20172024
Net Income−$12M
20172024
Operating CF−$11M
20172024
Free Cash Flow−$11M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue——$0.0B$0.0B————
Cost of Revenue————————
Gross Profit————————
R&D Expense—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense——————$0.0B—
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-3.87$-8.48$-1.70————$-0.06
EPS (Diluted)$-3.87$-8.48—————$-0.06

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.0B———$-0.0B$-0.0B$0.0B
Capital Expenditures$0.0B$0.0B————$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$-0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies